Greater area under the hemoglobin change curve is associated with improved outcomes in breast cancer patients receiving epoetin alfa for chemotherapy-related anemia.

被引：0

|

作者：

Lefebvre, P

Duh, MS

McKenzie, RS

Piech, CT

机构：

[1] Grp Anal Ltee, Montreal, PQ, Canada

[2] Anal Grp Inc, Boston, MA USA

[3] Ortho Biotech Clin Affairs LLC, Bridgewater, NJ USA

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 94卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

收藏

页码：S214 / S215

页数：2

相关论文

共 22 条

[1] Greater area under the hemoglobin change curve is associated with improved outcomes in elderly patients receiving epoetin alfa for chemotherapy-related anemia
McKenzie, SR
Duh, MS
Lefevbre, P
Fastenau, JM
Piech, CT
BLOOD, 2004, 104 (11) : 860A - 860A
[2] Greater area under the hemoglobin change curve is associated with improved outcomes in patients receiving epoetin alfa (EPO) or darbepoetin alfa (DARB) for chemotherapy-related anemia (CRA).
Lefebvre, P
Duh, MS
McKenzie, RS
Mody, SH
Woodman, RC
Williams, D
PHARMACOTHERAPY, 2005, 25 (10): : 1469 - 1469
[3] Benefits of early hemoglobin response to epoetin alfa in elderly patients with chemotherapy-related anemia.
Rosberg, J
Cremieux, PY
McKenzie, SR
Fastenau, JM
Piech, CT
BLOOD, 2004, 104 (11) : 609A - 609A
[4] Greater area under the hemoglobin change curve during epoetin alfa treatment is associated with improved patient outcomes
Lefebvre, P
Fastenau, JM
Duh, MS
Cremieux, P
McKenzie, RS
Piech, CT
VALUE IN HEALTH, 2004, 7 (03) : 317 - 317
[5] Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy
Quirt, I
Robeson, C
Lau, CY
Kovacs, M
Burdette-Radoux, S
Dolan, S
Tang, SC
McKenzie, M
Couture, F
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (21) : 4126 - 4134
[6] SAFETY AND EFFICACY OF ORAL LIPOSOMAL IRON SUPPLEMENTED IN CANCER PATIENTS WITH CHEMOTHERAPY-RELATED ANEMIA RECEIVING EPOETIN ALFA. FINAL DATA
Prestifilippo, A.
Mafodda, A.
Maisano, R.
Giuffrida, D.
Mare, M.
Azzarello, D.
Blanco, G.
Nardi, M.
ANNALS OF ONCOLOGY, 2012, 23 : 505 - 505
[7] Clinical benefits and risks associated with darbepoetin alfa and epoetin alfa treatment in patients with lung cancer and chemotherapy-induced anemia.
Tiotiu, Angelica
Clerc-Urmes, Isabelle
Chabot, Francois
Martinet, Yves
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[8] Cost of managing anemia with and without prophylactic epoetin alfa therapy in breast cancer patients receiving combination chemotherapy
Meadowcroft, AM
Gilbert, CJ
Maravich-May, D
Hayward, SL
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1998, 55 (18) : 1898 - 1902
[9] Weekly epoetin alfa (QW) provides similar hematologic outcomes to front-loading (FL) darbepoetin alfa regimens and better outcomes compared to darbepoetin alfa (Q2W) in patients with chemotherapy-related anemia.
Duh, MS
Lefebvre, P
Dector, AJ
Watson, SH
McKenzie, SR
Piech, CT
BLOOD, 2003, 102 (11) : 511B - 512B
[10] Epoetin alfa and darbepoetin alfa for the treatment of chemotherapy-related anemia in cancer patients in Sweden: Comparative analysis of drug utilization, costs, and hematologic response
Ulf Persson
Sixten Borg
Sandra Jansson
Tor Ekman
Lars Franksson
Signe Friesland
Anna-Maria Larsson
Advances in Therapy, 2005, 22 : 208 - 224